RCS - Roquefort Theraptcs. - Research Note Published

Roquefort TherapeuticsAnnouncement

15/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260115:nRSO9354Oa&default-theme=true

RNS Number : 9354O  Roquefort Therapeutics PLC  15 January 2026

15 January 2026

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

 

              Research Note Published

 

Roquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company,
announces that a new research note regarding the Company's proposed
transaction with Coiled Therapeutics, Inc. and A2A Pharmaceuticals, Inc., as
first announced on 8 September 2025, has been published by its broker SP Angel
Corporate Finance LLP.

 

It can be accessed by the following link:
https://www.roquefortplc.com/analyst-research
(https://www.roquefortplc.com/analyst-research)

 

 

ENDS

 

Enquiries:
 
 Roquefort Therapeutics plc                               +44 (0)20 3918 8633
 Stephen West (Chairman) / Dr Darrin Disley (Interim MD)
 SP Angel Corporate Finance LLP (Broker to the Company)   +44 (0)20 3470 0470

 David Hignell / Vadim Alexandre / Devik Mehta
 Shard Capital Partners LLP (Broker to the Company)       +44 (0)20 4530 6926

 Damon Heath
 Burson Buchanan (Public Relations)                       +44 (0)20 7466 5000

 Ben Romney / Jamie Hooper

 

LEI: ‎254900P4SISIWOR9RH34

 

For further information on Roquefort Therapeutics,
please visit www.roquefortplc.com (http://www.roquefortplc.com/)

 

About Coiled Therapeutics Inc. ("Coiled USA")

Coiled USA is a clinical stage oncology company and is a spin-out of A2A
Pharmaceuticals, Inc. Coiled USA holds the exclusive worldwide rights to
AO-252, a novel, brain-penetrant small molecule inhibitor designed to disrupt
TACC3 protein-protein interactions.  Coiled USA has advanced the AO-252
program through pre-clinical development and IND approval and commenced Phase
I trials in the USA (trials ID: NCT06136884).  Coiled USA is actively
enrolling patients to test for safety and efficacy in patients whose cancer
has progressed on other treatments.

 

About A2A Pharmaceuticals, Inc. ("A2A Pharmaceuticals")

A2A Pharmaceuticals is a private, well-funded company that uses proprietary
computational systems, including generative AI with its SCULPT™ platform to
accelerate the development of novel drug alternatives for life threatening
diseases like cancer.  This enables a more efficient process than traditional
trial and error approaches to drug discovery.

 

A2A Pharmaceuticals aims to develop therapies to early clinical stages and
then spin them out into standalone entities to progress them through clinical
development.  In 2018,  A2A Pharmaceuticals spun out its MLL-Menin program
to Biomea Fusion, Inc. ("Biomea Fusion"), a company that completed an IPO on
Nasdaq in 2021 raising US$153 million and listing with a market capitalisation
of US$464 million.  Post-IPO Biomea Fusion's market capitalisation reached a
peak of over US$1 billion.

 

Further information on A2A Pharmaceuticals can be found at:
https://www.a2apharma.com/ (https://www.a2apharma.com/)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASFUFMLEMSEEF



            Copyright 2019 Regulatory News Service, all rights reserved